📇 Rhumatologue ·

MME NICOLE HUDUT

Pourquoi vous devez consulter ce praticien

1 raison identifiée

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche

Rhumatologue

RPPS 10001018950

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib 📇 Ajouter à mes contacts

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer

Journal of the National Cancer Institute · 2024

📚 29 citations🎯 RCR 3.89Top 11% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background The cutoff of &lt;1% positive cells to define estrogen receptor (ER) negativity by immunohistochemistry (IHC) in breast cancer (BC) is debated. We explored the tumor immune microenvironment and gene-expression profile of patients with early-stage HER2-negative ER-low (ER 1%-9%) BC, comparing them to ER-negative (ER &lt;1%) and ER-intermediate (ER 10%-50%) tumors. Methods Among 921 patients with early-stage I-III, ER ≤50%, HER2-negative BCs, tumors were classified as ER-negative (n = 712), ER-low (n = 128), or ER-intermediate (n = 81). Tumor-infiltrating lymphocytes (TILs) were evaluated. CD8+, FOXP3+ cells, and PD-L1 status were assessed by IHC and quantified by digital pathology. We analyzed 776 BC-related genes in 116 samples. All tests were 2-sided at a &lt;.05 significance level. Results ER-low and ER-negative tumors exhibited similar median TILs, statistically significantly higher than ER-intermediate tumors. CD8/FOXP3 ratio and PD-L1 positivity rates were comparable between ER-low and ER-negative groups. These groups showed similar enrichment in basal-like intrinsic subtypes and comparable expression of immune-related genes. ER-low and ER-intermediate tumors showed significant transcriptomic differences. High TILs (≥30%) were associated with improved relapse-free survival (RFS) in ER-low (5-year RFS 78.6% vs 66.2%, log-rank P = .033, hazard ratio [HR] 0.37 [95% CI = 0.15 to 0.96]) and ER-negative patients (5-year RFS 85.2% vs 69.8%, log-rank P &lt; .001, HR 0.41 [95% CI = 0.27 to 0.60]). Conclusions ER-low and ER-negative tumors are similar biological and molecular entities, supporting their comparable clinical outcomes and treatment responses, including to immunotherapy. Our findings contribute to the growing evidence calling for a reevaluation of ER-positive BC classification and management, aligning ER-low and ER-negative tumors more closely.

Tumor budding to investigate local invasion, metastasis, and prognosis of head and neck carcinoma: A systematic review

Head & neck · 2024

📚 15 citations🎯 RCR 3.67Top 12% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractThe aim of this systematic review is to shed light on the role of tumor budding (TB) in the biology, behavior, and prognosis of head and neck squamous cell carcinoma (HNSCC). A search was run in PubMed, Scopus, and Embase databases following PRISMA guidelines. After full‐text screening and application of inclusion/exclusion criteria, 36 articles were included. Several investigations support the prognostic role of TB, which might play a role in selecting rational treatment strategies. To achieve this goal, further research is needed for greater standardization in TB quantification. Although TB is not included as a negative prognostic factor in the current management guidelines, it might be reasonable to consider a closer follow‐up for HNSCC cases with high histopathological evidence of TB.

Ketamine alleviates NMDA receptor hypofunction through synaptic trapping

Neuron · 2024

📚 13 citations🎯 RCR 2.25Top 23% NIH🔓 Open Access

Cookies & analyse de trafic

MME NICOLE HUDUT

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal34

Revue générale4

Vraie vie / RWE4

Pharmacovigilance3

Revue / méta-analyse2

Biomarqueurs / Auto-Ac1

Case report / série1

Épidémiologie & registres1

Essai clinique1

Gériatrie1

Lupus1

Ostéoporose1

Recommandations1

Santé mentale / fatigue1

Vascularites des gros vaisseaux1

Partager cette fiche